Pharmacophore and docking-based combined in-silico study of KDR inhibitors

被引:48
作者
Pasha, F. A. [3 ]
Muddassar, M. [3 ,4 ]
Neaz, M. M. [3 ,4 ]
Cho, Seung Joo [1 ,2 ]
机构
[1] Chosun Univ, Res Ctr Resistant Cells, Kwangju 501759, South Korea
[2] Chosun Univ, Coll Med, Kwangju 501759, South Korea
[3] Korea Inst Sci & Technol, Future Fus Technol Div, Computat Sci Ctr, Seoul 130650, South Korea
[4] Univ Sci & Technol, Taejon, South Korea
关键词
3D-QSAR; Drug design; Pharmacophore; Docking; CoMFA; CoMSIA; VEGFR; GROWTH-FACTOR RECEPTOR-2; TYROSINE KINASE; QSAR; DERIVATIVES; MOLECULES; BINDING; COMFA; TIE-2; FIELD; HELP;
D O I
10.1016/j.jmgm.2009.04.006
中图分类号
Q5 [生物化学];
学科分类号
070307 [化学生物学];
摘要
The growth and metastasis of solid tumors is dependent on angiogenesis. The vascular endothelial growth factor (VEGF) and its cell surface receptor in human KDR (kinase domain containing receptor or VEGFR-2) have particular interest because of their importance in angiogenesis. The development of novel inhibitors of VEGFR-2 would be helpful to check the growth of tumors. Quantitative structure activity relationship (QSAR) analyses used to understand the structural factors affecting inhibitory potency of thiazole-substituted pyrazolone derivatives. Several pharmacophore-based models indicated the importance of steric, hydrophobic and hydrogen bond acceptor groups to inhibitory activity. The comparative molecular field analyses (CoMFA) and comparative molecular similarity indices analyses (CoMSIA) based 3D-QSAR models were derived using pharmacophore-based alignment. Both CoMFA (q(2) = 0.70, r(2) = 0.97 and r(predictive)(2) = 0.61) and CoMSIA (q(2) = 0.54, r(2) = 0.82 and r(predictive)(2) = 0.66) gave reasonable results. The molecular docking (receptor-guided technique) with a recently reported receptor structure (PDB = 1YWN) were performed. The docked alignment was subsequently used for 3D-QSAR (CoMFA; q(2) = 0.56, r(2) = 0.97, r(predictive)(2) = 0.82, CoMSIA; q(2) = 0.58 r(2) = 0.91, r(predictive)(2) = 0.69). The overall both studies were indicated, steric, electrostatic and hydrogen bond acceptor effects contribute to the inhibitory activity. CoMFA and CoMSIA models suggested that a positive bulk with hydrophobic effect is desirable around position 4 and 5 and hydrogen bond acceptor groups around pyrazolones ring will be helpful. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:54 / 61
页数:8
相关论文
共 28 条
[1]
Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors [J].
Borzilleri, RM ;
Zheng, XP ;
Qian, LG ;
Ellis, C ;
Cai, ZW ;
Wautlet, BS ;
Mortillo, S ;
Jeyaseelan, R ;
Kukral, DW ;
Fura, A ;
Kamath, A ;
Vyas, V ;
Tokarski, JS ;
Barrish, JC ;
Hunt, JT ;
Lombardo, LJ ;
Fargnoli, J ;
Bhide, RS .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (12) :3991-4008
[2]
COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967
[3]
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors [J].
Dai, YJ ;
Guo, Y ;
Frey, RR ;
Ji, ZQ ;
Curtin, ML ;
Ahmed, AA ;
Albert, DH ;
Arnold, L ;
Arries, SS ;
Barlozzari, T ;
Bauch, JL ;
Bouska, JJ ;
Bousquet, PF ;
Cunha, GA ;
Glaser, KB ;
Guo, J ;
Li, JL ;
Marcotte, PA ;
Marsh, KC ;
Moskey, MD ;
Pease, LJ ;
Stewart, KD ;
Stoll, VS ;
Tapang, P ;
Wishart, N ;
Davidsen, SK ;
Michaelides, MR .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (19) :6066-6083
[4]
THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991
[5]
CALCULATION OF THE CHARGE-DISTRIBUTION IN CONJUGATED SYSTEMS BY A QUANTIFICATION OF THE RESONANCE CONCEPT [J].
GASTEIGER, J ;
SALLER, H .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1985, 24 (08) :687-689
[6]
Geladi P., 1988, J CHEMOM, V2, P231
[7]
Discovery of novel Benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors [J].
Hasegawa, Masaichi ;
Nishigaki, Naohiko ;
Washio, Yoshiaki ;
Kano, Kazuya ;
Harris, Philip A. ;
Sato, Hideyuki ;
Mori, Ichiro ;
West, Rob I. ;
Shibahara, Megumi ;
Toyoda, Hiroko ;
Wang, Liping ;
Nolte, Robert T. ;
Veal, James M. ;
Cheung, Mui .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (18) :4453-4470
[8]
DEVELOPMENTAL EXPRESSION OF BINDING-SITES AND MESSENGER-RIBONUCLEIC-ACID FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR SUGGESTS A ROLE FOR THIS PROTEIN IN VASCULOGENESIS AND ANGIOGENESIS [J].
JAKEMAN, LB ;
ARMANINI, M ;
PHILLIPS, HS ;
FERRARA, N .
ENDOCRINOLOGY, 1993, 133 (02) :848-859
[9]
Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides [J].
Kaminski, GA ;
Friesner, RA ;
Tirado-Rives, J ;
Jorgensen, WL .
JOURNAL OF PHYSICAL CHEMISTRY B, 2001, 105 (28) :6474-6487
[10]
A critical review of recent CoMFA applications [J].
Kim, KH ;
Greco, G ;
Novellino, E .
PERSPECTIVES IN DRUG DISCOVERY AND DESIGN, 1998, 12 :257-315